The purpose of this study is to assess the effectiveness of high intensity laser therapy in the treatment of subacromial impingement syndrome.
Shoulder pain has a high prevalence in our society, several studies estimate an annual prevalence between 5% and 47%. It is one of the main causes of musculoskeletal pain, particularly in third place, after the low back pain and neck pain. Symptoms of pathologies of subacromial space impingement syndrome, where, regardless of origin, pain is the number one symptom for the patient, which emanates functional impairment and the impact on quality of life. Because of the need to implement research to assess the effectiveness of high intensity laser therapy with new studies mayor methodological quality of obtaining conclusive results, and based on the scientific evidence supporting the low-power laser therapy as a useful tool in addressing the shoulder tendon pathology, we consider very interesting the realization of this research project.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
46
Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy) \+ Physical Therapy protocol.
Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
Hospital General Nuestra Señora del Prado
Talavera de la Reina, Toledo, Spain
Shoulder Pain and Disability Index (SPADI)
SPADI test
Time frame: Baseline
Shoulder Pain and Disability Index (SPADI)
SPADI test
Time frame: At the end of the laser protocol treatment (1 daily session during 15 workday -from monday to friday-)
Shoulder Pain and Disability Index (SPADI)
SPADI test
Time frame: one month after the end of the protocol treatment
Shoulder Pain and Disability Index (SPADI)
SPADI test
Time frame: three months after the end of the protocol treatment
Constant-Murley Score
Constant-Murley Score without strength section. The results will be expressed on a maximum of 75 points.
Time frame: Baseline
Constant-Murley Score
Constant-Murley Score without strength section. The results will be expressed on a maximum of 75 points.
Time frame: At the end of the laser protocol treatment (1 daily session during 15 workday -from monday to friday-)
Constant-Murley Score
Constant-Murley Score without strength section. The results will be expressed on a maximum of 75 points.
Time frame: one month after the end of the protocol treatment
Constant-Murley Score
Constant-Murley Score without strength section. The results will be expressed on a maximum of 75 points.
Time frame: three months after the end of the protocol treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Quick-Dash Abbreviated
Quick- Dash Abbreviated test
Time frame: Baseline
Quick-Dash Abbreviated
Quick- Dash Abbreviated test
Time frame: At the end of the laser protocol treatment (1 daily session during 15 workday -from monday to friday-)
Quick-Dash Abbreviated
Quick- Dash Abbreviated test
Time frame: one month after the end of the protocol treatment
Quick-Dash Abbreviated
Quick- Dash Abbreviated test
Time frame: three months after the end of the protocol treatment
Painful pressure threshold
The pressure pain threshold will be measured by a pressure algometer and will be expressed in Newton.
Time frame: Baseline, at the of the 15 sessions, one month after the end of the protocol treatment, three months after the end of the protocol treatment
Painful pressure threshold after first session
The pressure pain threshold will be measured by a pressure algometer and will be expressed in Newton.
Time frame: First session - 15 minutes after laser or sham treatment.
VAS
Visual analogue scale
Time frame: Baseline, at the of the 15 sessions, one month after the end of the protocol treatment, three months after the end of the protocol treatment